Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Sarah A Schihl"'
Autor:
Lia Luus, Vasileios Askoxylakis, John Wilton, Alexey Lugovskoy, Kenneth J. Olivier, Stephanie Grabow, Jaeyeon Kim, Christine Pien, Geoffrey Kuesters, Suresh K. Tipparaju, Melissa Geddie, Nancy Dumont, Mark E. Hayes, Alexander Koshkaryev, Sarah A Schihl, C. Patrick Reynolds, Rachel Blaydes, Andrew J. Sawyer, James D. Marks, Tad Kornaga, James Suchy, Charles O. Noble, Dmitri B. Kirpotin, Shinji Oyama, Neeraj Kohli, Zhaohua Richard Huang, Walid S. Kamoun, Daryl C. Drummond, Yu Zhou
Publikováno v:
Nature Biomedical Engineering. 3:264-280
Antibody-mediated tumour targeting and nanoparticle-mediated encapsulation can reduce the toxicity of antitumour drugs and improve their efficacy. Here, we describe the performance of a nanotherapeutic encapsulating a hydrolytically sensitive docetax
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d8e94f819de7e7f6ccdf49b01d0fee2
https://doi.org/10.1038/s41551-019-0385-4
https://doi.org/10.1038/s41551-019-0385-4
Autor:
Charles LeVea, Grace K. Dy, Wei Tan, Laura Pitzonka, Patrick McKay Boland, Renuka Iyer, Alex A. Adjei, Hao Xie, Robert M. Straubinger, Sarah A Schihl, William E. Brady, Krystin Mantione, Amy Whitworth, Wen Wee Ma, Gerald J. Fetterly, John Wilton
Publikováno v:
American Journal of Clinical Oncology. 42:184-189
OBJECTIVES: Preclinical studies demonstrated antitumor activity of dovitinib in pancreatic cancer models. This phase Ib study aimed to determine the maximum tolerated dose of dovitinib in combination with gemcitabine and capecitabine and to character
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cc3babf7e001739ec14179f912c6003
https://doi.org/10.1097/coc.0000000000000492
https://doi.org/10.1097/coc.0000000000000492
Autor:
Gerald J. Fetterly, Renuka Iyer, Leslie Curtin, Daniel T. Fisher, Orla Maguire, Hans Minderman, Sarah A Schihl, Stephan Menne, Sandra Sexton, Minhyung Kim
Publikováno v:
Cancers
Volume 11
Issue 5
Cancers, Vol 11, Iss 5, p 681 (2019)
Volume 11
Issue 5
Cancers, Vol 11, Iss 5, p 681 (2019)
The multikinase inhibitor sorafenib is the only standard first-line therapy for hepatocellular carcinoma (HCC). Here, we report the dose-dependent effects of sorafenib on the immune response, which is related to nuclear factor of activated T cells 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51439cfa9af87df0a67c22862ee2048e
https://pubmed.ncbi.nlm.nih.gov/31100868
https://pubmed.ncbi.nlm.nih.gov/31100868
Autor:
Alexander Koshkaryev, Walid S. Kamoun, Birgit Schoeberl, Zhaohua Richard Huang, James D. Marks, Kenneth R. Olivier, Christine S. Pien, Tad Kornaga, Daryl C. Drummond, Gerald J. Fetterly, Dmitri B. Kirpotin, Charles O. Noble, Suresh K. Tipparaju, Shinji Oyama, Sarah S. Schihl, Mark E. Hayes
Publikováno v:
Cancer Research. 76:3912-3912
Taxanes are widely used to treat solid tumors either in the curative or palliative setting, in first or later lines of therapy. Analysis of docetaxel dose-response relationship strongly suggests that a higher dose would lead to high response, however
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e7f364e758686b143203440947d8c885
https://doi.org/10.1158/1538-7445.am2016-3912
https://doi.org/10.1158/1538-7445.am2016-3912
Autor:
Sandra Sexton, Sarah A Schihl, Leslie Curtin, Justin Caserta, Laura Pitzonka, Gerald J. Fetterly, Yvonne Flanders, Stephane Dumas, Carmen M. Baldino, Allison Gaudy
Publikováno v:
Cancer Research. 74:4647-4647
PIM2 is a serine/threonine protein kinase that has roles in cell growth, proliferation, and apoptosis via the regulation of multiple signal transduction cascades. JP_11646 is a novel PIM2 inhibitor that has shown antitumor activity against breast, co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::276c0ed22608ac61938b384f3b1ca9e7
https://doi.org/10.1158/1538-7445.am2014-4647
https://doi.org/10.1158/1538-7445.am2014-4647